Phase III trial of ciclosporin for the prevention of reperfusion injury after myocardial infarction in China.
Phase of Trial: Phase III
Latest Information Update: 26 May 2015
At a glance
- Drugs Ciclosporin (Primary)
- Indications Myocardial infarction; Reperfusion injury
- Focus Therapeutic Use
- 26 May 2015 According to NeuroVive Pharmaceutical media release, data from this trial will be used to seek market approval for CicloMulsion in a number of Asian countries for the treatment of reperfusion injury following myocardial infarct.
- 04 Jun 2013 New trial record
- 29 May 2013 An application to conduct this trial is being prepared for the Chinese health care regulation agency, according to a NeuroVive media release.